A1B use raises risk of vascular event
The risk of vascular events is increased with many alpha1-adrenergic receptor blockers used for the treatment of benign prostatic hyperplasia, a large meta-analysis shows.
Canadian researchers found A1B use was associated with an overall significant 2.5-fold increase in the risk of developing a vascular event.
But the odds differed depending on the agent used – with alfuzosin increasing risk 1.66-fold, terazosin by 3.7-fold, doxazosin by 3.3-fold and tamsulosin a non-significant 1.4-fold, compared with placebo.
However, all the drugs significantly improved urinary flow rate and symptom signs compared with placebo.